ENSCEnsysce Biosciences, Inc.

Nasdaq ensysce.com


$ 0.54 $ -0.01 (-2.13 %)    

Thursday, 25-Apr-2024 15:59:49 EDT
QQQ $ 428.00 $ 0.02 (0 %)
DIA $ 380.88 $ -3.52 (-0.92 %)
SPY $ 506.56 $ -1.63 (-0.32 %)
TLT $ 88.27 $ 0.00 (0 %)
GLD $ 217.28 $ 0.00 (0 %)
$ 0.5467
$ 0.56
$ 0.00 x 0
$ 0.00 x 0
$ 0.54 - $ 0.56
$ 0.53 - $ 7.20
59,748
na
1.24M
$ 1.24
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-14-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 05-15-2023 03-31-2023 10-Q
5 03-30-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-11-2022 06-30-2022 10-Q
8 05-12-2022 03-31-2022 10-Q
9 03-31-2022 12-31-2021 10-K
10 11-15-2021 09-30-2021 10-Q
11 08-16-2021 06-30-2021 10-Q
12 06-08-2021 03-31-2021 10-Q
13 03-15-2021 12-31-2020 10-K
14 11-09-2020 09-30-2020 10-Q
15 08-07-2020 06-30-2020 10-Q
16 05-07-2020 03-31-2020 10-Q
17 03-10-2020 12-31-2019 10-K
18 11-07-2019 09-30-2019 10-Q
19 08-07-2019 06-30-2019 10-Q
20 05-07-2019 03-31-2019 10-Q
21 03-11-2019 12-31-2018 10-K
22 11-07-2018 09-30-2018 10-Q
23 08-01-2018 06-30-2018 10-Q
24 05-03-2018 03-31-2018 10-Q
25 03-09-2018 12-31-2017 10-K
26 01-09-2018 09-30-2017 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ensysce-biosciences-q4-eps-113-misses-087-estimate-sales-51503k-beat-39000k-estimate

Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(1.13) per share which missed the analyst consensus estimate of...

 ensysce-biosciences-announces-the-co-may-continue-its-listing-on-the-nasdaq-capital-market-tier-with-an-extension-to-may-13-2024-in-order-to-demonstrate-compliance-with-the-equity-requirement-in-listing-rule-5550b1

Ensysce Biosciences, Inc. (the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to ...

 ensysce-biosciences-receives-fda-guidance-for-pf614-mpar-program

The meeting focused on the Company's non-clinical program for the combination product that is designed for the treatment of...

 why-amd-shares-are-trading-lower-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of Advanced Micro Devices, Inc. (NASDAQ: AMD) shares declined 3.8% to $165.49 following fourth-quarter results. AMD rep...

Core News & Articles

ENSC: 92% | Ensysce Biosciences Reports Completion Of A Constructive End Of Phase 2 Meeting With FDA Regarding Its Lead 'Ne...

 ensysce-biosciences-reports-completion-of-a-constructive-end-of-phase-2-meeting-with-fda-regarding-its-lead-next-generation-analgesic-pf614-phase-3-program-expected-to-begin-enrollment-in-mid-2024

"We are appreciative of the guidance provided by the FDA to help us properly position PF614 as we progress through clinical...

 ensysce-biosciences-to-present-oral-overdose-protection-for-opioids-at-the-5th-annual-nih-heal-meeting

Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ: ENSC), a clinical-stage biotech company applyin...

 why-blackberry-shares-are-trading-lower-by-over-17-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of BlackBerry Limited (NYSE: BB) fell sharply during Wednesday’s session after the company announced a proposed private ...

 why-netflix-shares-are-trading-higher-by-10-here-are-20-stocks-moving-premarket

Shares of Netflix, Inc. (NASDAQ: NFLX) shares rose sharply in today’s pre-market trading as the company reported better-than-e...

 crude-oil-down-1-lockheed-martin-earnings-top-views

U.S. stocks traded mixed toward the end trading, with the Dow Jones index falling around 100 points on Tuesday. The Dow traded...

 why-3m-shares-are-trading-lower-by-over-12-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of 3M Company (NYSE: MMM) fell sharply during Tuesday’s session after the company reported better-than-expected fourth-q...

 opioid-developer-ensysce-biosciences-stock-is-shooting-higher-today---heres-why

Ensysce Biosciences breakthrough in opioid innovation! FDA grants PF614-MPAR BTD for enhanced pain relief with overdose protect...

 dow-tumbles-150-points-procter--gamble-shares-rise-on-upbeat-earnings

U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 150 points on Tuesday. The Dow traded...

Core News & Articles

RUM: 19% | Rumble Announces Public Launch of Rumble Studio ENSC: 59% | Ensysce Biosciences Announces FDA Breakthrough Therapy ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION